Αποτελέσματα Αναζήτησης
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
11 Απρ 2024 · Sequential Adriamycin-cyclophosphamide therapy with paclitaxel or docetaxel (AC-T) was declared by a 2015 review to likely be the most effective treatment regimen of early-stage breast cancer regardless of hormone status.
Treatment overview. This treatment regimen consists of two parts: 4 cycles of AC dose dense followed by 4 cycles of PACLitaxel dose dense. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense.
14 Δεκ 2023 · Breast cancer is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behavior. Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene is present in approximately 15 percent of primary invasive breast cancers [1].
Pregnancy. Significant cardiovascular disease and/or LVEF less than 50%; if initial reading is less than 50%, physician may consider repeating for validity, or assessing LVEF by the other modality, e.g. echocardiogram instead of MUGA. Known hypersensitivity to E. coli derived products.
26 Μαΐ 2019 · Six cycles of adjuvant anthracycline-taxane-based chemotherapy compared with eight cycles for women with breast cancer. Authors: Michael Lee, Sheridan Wilson, and David James Porter Authors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 37, Number 15_suppl. https://doi.org/10.1200/JCO.2019.37.15_suppl.e12045. Abstract.
